Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 53.

Maquieira, R; Haerle, S K; Huber, G F; Soltermann, A; Haile, S R; Stoeckli, S J; Broglie, Martina A (2016). No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression. European Archives of Oto-Rhino-Laryngology, 273(7):1841-1848.

Darwiche, K; Ozkan, F; Ting, S; Johnen, G; Brüning, T; Soltermann, A; Huber, L C; Christoph, D C; Freitag, L; Franzen, D (2014). Prätherapeutische Biomarker des Lungenkarzinoms unter besonderer Berücksichtigung der Bronchoskopie. Pneumologie (Stuttgart, Germany), 68(11):719-726.

Warth, A; Cortis, J; Soltermann, A; Meister, M; Budczies, J; Stenzinger, A; Goeppert, B; Thomas, M; Herth, F J F; Schirmacher, P; Schnabel, P A; Hoffmann, H; Dienemann, H; Muley, T; Weichert, W (2014). Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. British Journal of Cancer, 111(6):1222-1229.

Otterstrom, C; Soltermann, A; Opitz, I; Felley-Bosco, E; Weder, W; Stahel, R A; Triponez, F; Robert, J H; Serre-Beinier, V (2014). CD74: a new prognostic factor for patients with malignant pleural mesothelioma. British Journal of Cancer, 110(8):2040-2046.

Broglie, M A; Soltermann, A; Rohrbach, D; Haile, S R; Pawlita, M; Studer, G; Huber, G F; Moch, H; Stoeckli, S J (2013). Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. Head and Neck, 35(12):1698-1706.

Broglie, M A; Soltermann, A; Haile, S R; Röösli, C; Huber, G F; Schmid, S; Stoeckli, S J (2013). Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. The Laryngoscope, 123(1):164-170.

Petrausch, U; Schuberth, P C; Hagedorn, C; Soltermann, A; Tomaszek, S; Stahel, R; Weder, W; Renner, C (2012). Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer, 12:615.

Morra, L; Rechsteiner, M; Casagrande, S; von Teichman, A; Schraml, P; Moch, H; Soltermann, A (2012). Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer, 76(2):183-190.

Wiedl, T; Collaud, S; Hillinger, S; Arni, S; Burgess, C; Kroll, W; Schraml, P; Soltermann, A; Moch, H; Weder, W (2012). KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. Cancer Genomics & Proteomics, 9(1):51-54.

Ziegler, A; Cerciello, F; Bigosch, C; Bausch-Fluck, D; Felley-Bosco, E; Ossola, R; Soltermann, A; Stahel, R A; Wollscheid, B (2012). Proteomic surfaceome analysis of mesothelioma. Lung Cancer, 75(2):189-196.

Haerle, S K; Strobel, K; Ahmad, N; Soltermann, A; Schmid, D T; Stoeckli, S J (2011). Contrast-enhanced (18)F-FDG-PET/CT for the assessment of necrotic lymph node metastases. Head and Neck, 33(3):324-329.

Palumbo, A; Hauler, F; Dziunycz, P; Schwager, K; Soltermann, A; Pretto, F; Alonso, C; Hofbauer, G F; Boyle, R W; Neri, D (2011). A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. British Journal of Cancer, 104(7):1106-1115.

Wiedl, T; Arni, S; Roschitzki, B; Grossmann, J; Collaud, S; Soltermann, A; Hillinger, S; Aebersold, R; Weder, W (2011). Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. Journal of Proteomics, 74(10):1884-1894.

Felley-Bosco, E; Opitz, I; Soltermann, A; Thies, S; Weder, W; Stahel, R A (2011). Asbestos-induced tissue regeneration and malignant pleural mesothelioma: Insights from developmental studies. In: Berhardt, L V. Advances in Medicine and Biology. Volume 34. Hauppauge NY, USA: Nova Science Publishers, 131-153.

Arbogast, S; Behnke, S; Opitz, I; Stahel, R A; Seifert, B; Weder, W; Moch, H; Soltermann, A (2011). Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297. Applied Immunohistochemistry & Molecular Morphology, 19(2):99-105.

Soltermann, A; Kilgus-Hawelski, S; Behnke, S; Storz, M; Moch, H; Bode, B (2011). Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. Journal of Clinical Bioinformatics, 1:25.

Busacca, S; Sheaff, M; Arthur, K; Gray, S G; O'Byrne, K J; Richard, D J; Soltermann, A; Opitz, I; Pass, H; Harkin, D P; Quinn, J E; Fennell, D A (2011). BRCA1 is an essential mediator of vinorelbine induced apoptosis in mesothelioma. Journal of Pathology:1-28.

Shi, Y; Hollenstein, A; Felley-Bosco, E; Fraefel, C; Ackermann, M; Soltermann, A; Weder, W; Stahel, R A; Pruschy, M; Opitz, I (2011). Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer, 71(3):370-371.

Huber, G F; Zullig, L; Soltermann, A; Roessle, M; Graf, N; Haerle, S K; Studer, G; Jochum, W; Moch, H; Stoeckli, S J (2011). Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer, 11:217.

Huber, G F; Albinger-Hegyi, A; Soltermann, A; Roessle, M; Graf, N; Haerle, S K; Holzmann, D; Moch, H; Hegyi, I (2011). Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. Cancer, 117(20):4659-4670.

Wagner, P L; Stiedl, A C; Wilbertz, T; Petersen, K; Scheble, V; Menon, R; Reischl, M; Mikut, R; Rubin, M A; Fend, F; Moch, H; Soltermann, A; Weder, W; Altorki, N K; Perner, S (2011). Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer, 74(1):118-123.

Jacobsen, C; Lübbers, H T; Obwegeser, J A; Soltermann, A; Grätz, K W (2011). Histological evaluation of microsurgical revascularized bone in the intraoral cavity: Does it remain alive? Microsurgery, 31(2):98-103.

Sidi, R; Pasello, G; Opitz, I; Soltermann, A; Tutic, M; Rehrauer, H; Weder, W; Stahel, R A; Felley-Bosco, E (2011). Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. European Journal of Cancer, 47(2):326-332.

Draenert, A; Marquardt, K; Inci, I; Soltermann, A; Weder, W; Jungraithmayr, W (2011). Ischaemia-reperfusion injury in orthotopic mouse lung transplants - a scanning electron microscopy study. International Journal of Experimental Pathology, 92(1):18-25.

Tischler, V; Pfeifer, M; Hausladen, S; Schirmer, U; Bonde, A K; Kristiansen, G; Sos, M L; Weder, W; Moch, H; Altevogt, P; Soltermann, A (2011). L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Molecular Cancer, 10:127.

Soltermann, A; Pache, J C; Vogt, P (2011). Metastasis of a pleural mesothelioma to a hyperplastic stomach polyp: an increase of vimentin expression is seen during a gain in deciduoid morphology. Rare Tumors, 3(4):e52.

Hammerman, P S; Sos, M L; Ramos, A H; Xu, C; Dutt, A; Zhou, W; Brace, L E; Woods, B A; Lin, W; Zhang, J; Deng, X; Lim, S M; Heynck, S; Peifer, M; Simard, J R; Lawrence, M S; Onofrio, R C; Salvesen, H B; Seidel, D; Zander, T; Heuckmann, J M; Soltermann, A; Moch, H; Koker, M; Leenders, F; Gabler, F; Querings, S; Ansén, S; Brambilla, E; Brambilla, C; Lorimier, P; Brustugun, O T; Helland, A; Petersen, I; Clement, J H; Groen, H; Timens, W; Sietsma, H; Stoelben, E; Wolf, J; Beer, D G; Tsao, M S; Hanna, M; Hatton, C; Eck, M J; Janne, P A; Johnson, B E; Winckler, W; Greulich, H; Bass, A J; Cho, J; Rauh, D; Gray, N S; Wong, K K; Haura, E B; Thomas, R K; Meyerson, M (2011). Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery, 1(1):78-89.

Frei, C; Opitz, I; Soltermann, A; Fischer, B; Moura, U; Rehrauer, H; Weder, W; Stahel, R; Felley-Bosco, E (2011). Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis, 32(9):1324-1332.

Morra, L; Rechsteiner, M; Casagrande, S; Duc Luu, V; Santimaria, R; Diener, P A; Sulser, T; Kristiansen, G; Schraml, P; Moch, H; Soltermann, A (2011). Relevance of periostin splice variants in renal cell carcinoma. American Journal of Pathology, 179(3):1513-1521.

Maier, S; Wilbertz, T; Braun, M; Scheble, V; Reischl, M; Mikut, R; Menon, R; Nikolov, P; Petersen, K; Beschorner, C; Moch, H; Kakies, C; Protzel, C; Bauer, J; Soltermann, A; Fend, F; Staebler, A; Lengerke, C; Perner, S (2011). SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Human Pathology, 42(8):1078-1088.

Wilbertz, T; Wagner, P; Petersen, K F; Stiedl, A C; Scheble, V J; Maier, S; Reischl, M; Mikut, R; Altorki, N K; Moch, H; Fend, F; Staebler, A; Bass, A J; Meyerson, M; Rubin, M A; Soltermann, A; Lengerke, C; Perner, S (2011). SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathology, 24(7):944-953.

Theurillat, J P; Metzler, S C; Henzi, N; Djouder, N; Helbling, M; Zimmermann, A K; Jacob, F; Soltermann, A; Caduff, R; Heinzelmann-Schwarz, V; Moch, H; Krek, W (2011). URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell, 19(3):317-332.

Schramm, A; Opitz, I; Thies, S; Seifert, B; Moch, H; Weder, W; Soltermann, A (2010). Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. European Journal of Cardio-Thoracic Surgery, 37(3):566-572.

Pedretti, M; Rancic, Z; Soltermann, A; Herzog, B A; Schliemann, C; Lachat, M; Neri, D; Kaufmann, P A (2010). Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis, 208(2):382-389.

Bhure, U N; Lardinois, D; Kalff, V; Hany, T F; Soltermann, A; Seifert, Burkhardt; Steinert, H C (2010). Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements. British Journal of Radiology, 83(994):841-849.

Soltermann, A; Opitz, I; Tischler, V; Thies, S; Morra, L; Stahel, R A; Weder, W; Moch, H (2010). EMT in NSCLC and malignant pleural mesothelioma. memo - Magazine of European Medical Oncology, 3(4):180-184.

Soltermann, A. Epithelial-mesenchymal transition in thoracic malignancies. 2010, University of Zurich, Faculty of Medicine.

Riener, M O; Fritzsche, F R; Soll, C; Pestalozzi, B C; Probst-Hensch, N M; Clavien, P A; Jochum, W; Soltermann, A; Moch, H; Kristiansen, G (2010). Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology, 56(5):600-606.

Weiss, J; Sos, M L; Seidel, D; et al; Soltermann, A; Moch, H (2010). Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine, 2(62):62ra93.

Collaud, S; Wiedl, T; Cattaneo, E; Soltermann, A; Hillinger, S; Weder, W; Arni, S (2010). Laser-capture microdissection impairs activity-based protein profiles for serine hydrolase in human lung adenocarcinoma. Journal of Biomolecular Techniques, 21(1):25-28.

Tischler, V; Fritzsche, F R; Wild, P J; Stephan, C; Seifert, H H; Riener, M O; Hermanns, T; Mortezavi, A; Gerhardt, J; Schraml, P; Jung, K; Moch, H; Soltermann, A; Kristiansen, G (2010). Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 10:273.

Pedretti, M; Soltermann, A; Arni, S; Weder, W; Neri, D; Hillinger, S (2009). Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer, 64(1):28-33.

Ampollini, L; Soltermann, A; Felley-Bosco, E; Lardinois, D; Arni, S; Speck, R F; Weder, W; Opitz, I (2009). Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. European Journal of Cardio-Thoracic Surgery, 35(3):457-462.

Ring, B Z; Seitz, R S; Beck, R A; Shasteen, W J; Soltermann, A; Arbogast, S; Robert, F; Schreeder, M T; Ross, D T (2009). A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Modern Pathology, 22(8):1032-1043.

Huber, L C; Soltermann, A; Fischler, M; Gay, S; Weder, W; Russi, E W; Speich, R; Ulrich, S (2009). Caveolin-1 Expression and Hemodynamics in COPD Patients. Open Respiratory Medicine Journal, 3:73-78.

Soltermann, A; Tischler, V (2009). EGFR-Status beim Lungen-Adeno-Ca. Leading Opinions. Hämatologie & Onkologie, (5):64-66.

Soltermann, A; Moch, H (2009). Klinisch relevante Biomarker des nicht kleinzelligen Lungenkarzinoms. Diagnostik, Prognose, Therapie und Prävention. The Medical Journal (TMJ), 2009(4):26-29.

Perner, S; Wagner, P L; Soltermann, A; LaFargue, C; Tischler, V; Weir, B A; Weder, W; Meyerson, M; Giordano, T J; Moch, H; Rubin, M A (2009). TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. Journal of Pathology, 217(1):65-72.

Soltermann, A; Tischler, V; Arbogast, S; Braun, J; Probst-Hensch, N M; Weder, W; Moch, H; Kristiansen, G (2008). Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clinical Cancer Research, 14(22):7430-7437.

Perner, S; Wagner, P L; Demichelis, F; Mehra, R; LaFargue, C J; Moss, B J; Arbogast, S; Soltermann, A; Weder, W; Giordano, T J; Beer, D G; Rickman, D S; Chinnaiyan, A M; Moch, H; Rubin, M A (2008). EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia, 10(3):298-302.

Schmitt, A M; Riniker, F; Anlauf, M; Schmid, S; Soltermann, A; Moch, H; Heitz, P U; Klöppel, G; Komminoth, P; Perren, A (2008). Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. American Journal of Surgical Pathology, 32(3):420-425.

Soltermann, A; Ossola, R; Kilgus-Hawelski, S; von Eckardstein, A; Suter, T; Aebersold, R; Moch, H (2008). N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer, 114(2):124-133.

Opitz, I; Soltermann, A; Abaecherli, M; Hinterberger, M; Probst-Hensch, N; Stahel, R; Moch, H; Weder, W (2008). PTEN expression is a strong predictor of survival in mesothelioma patients. European Journal of Cardio-Thoracic Surgery, 33(3):502-506.

This list was generated on Thu Sep 21 17:22:49 2017 CEST.